Issue link: https://beckershealthcare.uberflip.com/i/1119391
28 DEVICES & IMPLANTS NuVasive Board Chairman Gregory Lucier partners with private equity firm to launch new company: 5 things to know By Laura Dyrda F ormer NuVasive CEO Gregory Lucier part- nered with Chicago-based private equity firm GTCR to form a new healthcare company. Five things to know: 1. Under the partnership, GTCR will invest in Mr. Lucier's new company, Corza Health, from GTCR Fund XII, a private equity fund that includes $5.25 billion of equity capital commitments. 2. Mr. Lucier will serve as CEO of San Diego-based Corza Health and make a substantial investment in the company. 3. Corza Health will build a healthcare business fo- cused on life sciences and medical technology. Tradi- tionally, GTCR has partnered with management lead- ers to identify, acquire and build companies through acquisitions and organic growth. 4. Prior to his time with NuVasive, Mr. Lucier spent more than a decade as chairman and CEO of Life Technologies, growing the company's revenue from $700 million to $4 billion during his tenure. He also gained experience in mergers and acquisitions, inte- grating more than 20 add-on acquisitions. 5. Mr. Lucier is still listed as chairman of the board for NuVasive. n Stryker strengthens sports medicine line with up to $220M acquisition — 5 key notes By Laura Dyrda S tryker acquired OrthoSpace, an Israel-based company fo- cused on technology to treat irreparable rotator cuff tears. Four key notes: 1. Stryker agreed to pay $110 million in cash upfront for Ortho- Space and pay an additional $110 million if the company meets future milestones. 2. The company expects this acquisition to have an immaterial im- pact on 2019 net earnings. 3. OrthoSpace's InSpace is a biodegradable sub-acromial spacer designed to realign the natural biomechanics of the shoulder. More than 20,000 patients have been treated with the technology. 4. InSpace is under clinical study in the U.S. and hasn't received regulatory approval for use. 5. This acquisition complements Stryker's portfolio of orthopedic products and aligns with the company's mission to invest in sports medicine. "We are excited about the momentum OrthoSpace has in key global markets and the additional surgical option this tech- nology provides our customers to address a complex pathology," said Andy Pierce, Stryker's group president of Medsurg. n Zimmer Biomet earns FDA 510(k) clearance for Rosa One Spine System — 4 insights By Eric Oliver T he FDA granted Zimmer Biomet FDA 510(k) clearance for the minimally invasive Rosa One Spine System. What you should know: 1. Surgeons use the Rosa One Spine System for robotically assisted minimally invasive spine surgery and complex spine surgery. 2. The system also provides navigation support. 3. The system is part of Zimmer Biomet's Rosa One Brain and Rosa Knee portfolio. 4. Zimmer Biomet Group President of Spine Aure Bruneau said, "Rosa One Spine functions as a dual robotics and navigation tech- nology solution for minimally invasive and complex thoracolumbar spine procedures." n